FINNENCE ▪ THE WIRE FILE
THE WIRE · № 61681
News■ Unclear/unknown
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 2026
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 11:00 UTC
LAST UPDATE2026-10-02 11:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Early-phase combo data selection signals pipeline progress but no efficacy results yet disclosed.
Pipeline milestone, results still pending
CATALYST TO WATCH
Interim data presented at SITC 2026
MAIN RISK
Interim Phase 2 data may disappoint
FULL DISPATCH
STARt-002 is the first clinical study to combine a Vβ6-selective T-cell agonist with an ADC, pairing invikafusp alfa's selective T-cell activation with TRODELVY's TROP2-directed delivery of a cytotoxic payload Oral presentation will feature interim clinical results from two distinct...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare, LLY
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals2026-10-02 11:18 UTC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals2026-10-02 11:18 UTC
→CORRELATIONshares Healthcare
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 10:57 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 10:57 UTC
→CORRELATIONshares Healthcare
Afya (AFYA) Stock Looks Cheap Following A Fresh Merger Agreement2026-10-02 11:45 UTC
Afya (AFYA) Stock Looks Cheap Following A Fresh Merger Agreement2026-10-02 11:45 UTC
→CORRELATIONshares Healthcare, LLY
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
←CORRELATIONshares LLY
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
←CORRELATIONshares LLY
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.